Investigation of incidental findings of temporomandibular joint disorders on brain magnetic resonance imaging in three-dimensional T2-weighted SPACE sequence performed for brain imaging.

Objectives: The study aimed to determine the temporomandibular joint (TMJ) findings, to investigate the prevalence contribution of this sequence on cases in which cranial magnetic resonance examination was performed and three-dimensional (3D) T2-SPACE (T2-weighted sampling perfection with application-optimized contrasts using different flip-angle evolutions) sequence was used by retrospectively scanning the magnetic resonance imaging (MRI) archive of our hospital, and to reveal the advantages of the 3D-T2 SPACE sequence in patients with TMJ disorders. Patients and methods: The cross-sectional retrospective study was conducted with 499 patients (289 females, 210 males; mean age: 50.1±17.7 years; range, 8 to 92 years) who underwent brain MRI and had 3D-T2 SPACE between March 1, 2021 and March 1, 2022. Two radiologists analyzed the TMJs of the subjects included in the study in 3D-T2 SPACE sequences. Results: At least one incidental finding was detected in the TMJ in 37.1% (n=185) of the patients included in our study. In our study, the most common (13.6%) MRI findings were osteoarthritic changes and synovial cysts. Joint effusion (13.2%) and disc displacement (9%) were less frequent. When the relationship between the age of the patients and the presence of incidental findings, degeneration, effusion, disc displacement, and cyst was examined, the age of the patients with incidental findings (p=0.001) and osteoarthritic changes (p<0.001) was statistically significantly higher. Conclusion: Incidental findings, particularly osteoarthritic changes and synovial cysts, can be seen quite commonly in the TMJ in brain MRI using 3D T2-SPACE sequences in the general population. The 3D T2-SPACE sequence provides valuable information in the recognition of TMJ disorders.

An investigation of serum irisin levels and inflammatory markers in fibromyalgia syndrome.

OBJECTIVE: In the present study, we aimed to compare serum irisin levels in patients with fibromyalgia syndrome (FMS) and healthy control subjects and also investigate the relationship between irisin, disease activity and inflammation markers in patients. METHODS: A total of 84 women, including 48 patients who were diagnosed with FMS and 36 healthy controls, were included in this study. The demographic characteristics of the patients and control group were recorded. VAS for pain and the Fibromyalgia Impact Questionnaire for the assessment of the physical function of the patients, SF36 was used for quality of life, and accompanying Beck Depression Inventory to assess depression was used. Blood samples were taken for analysis that irisin, and inflammatory markers of the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), high-sensitivity C-reactive protein (hs-CRP) and neutrophil/lymphocyte ratio (NLO). Serum irisin levels were determined using the Enzyme-Linked Immunosorbent Assay (ELISA) method. RESULTS: Serum irisin level of the patients with FMS had no significant differences compared with the healthy control group. When we compared the values of ESR, CRP, hsCRP, NLO with FMS patients and healthy controls, there was no significant difference found between them (p>0.05). There was no significant correlation between inflammatory markers and level of serum irisin (p>0.05). In patients, there was no significant correlation between inflammatory markers and level of serum irisin (p>0.05). CONCLUSION: Irisin, which is a myokine, was determined to have no significant role in the pathogenesis of FMS. Irisin had no association with disease activity and inflammatory markers. Also, the inflammation hypothesis was not supported, which suggested in FMS.

The relationship between serum leptin level and disease activity and inflammatory markers in fibromyalgia patients.

OBJECTIVE: The aim of this study was to investigate whether there is a correlation between serum leptin level, disease activity and inflammation markers in patients with fibromyalgia syndrome (FMS). METHODS: A total of 48 patients with FMS diagnosed according to the 1990 American College of Rheumatology criteria were included in the study, as well as 36 healthy women as controls. The Visual Analogue Scale was used to gauge pain severity, the Fibromyalgia Impact Questionnaire was used to assess physical function, the 36-Item Short Form Health Survey was used to examine quality of life, and depression was measured with the Beck Depression Inventory. Blood samples were examined for erythrocyte sedimentation rate (ESR), C-reactive protein level (CRP), high-sensitivity CRP level (hsCRP), the neutrophil-to-lymphocyte ratio (NLR), and the serum leptin level was determined using the enzyme-linked immunosorbent assay method. RESULTS: The serum leptin level in patients with FMS was significantly higher than in the healthy group. However, no significant relationship was found between leptin level and clinical and inflammatory parameters. In addition, there were no significant differences between the patients and the control group in measurements of ESR, CRP, hsCRP, or NLR. CONCLUSION: A higher serum leptin level in patients with FMS suggested that leptin may play role in the pathogenesis of FMS, yet there was no relationship between leptin and clinical and inflammatory parameters, suggesting that leptin is not an indicator of disease activity in FMS. Additional research should be performed with larger patient groups.